vs
Forian Inc.（FORA）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是Forian Inc.的1.1倍（$9.1M vs $8.0M），Forian Inc.净利率更高（-22.9% vs -60.3%，领先37.5%），Forian Inc.同比增速更快（37.0% vs -49.9%），过去两年Forian Inc.的营收复合增速更高（27.8% vs -6.7%）
Forian Inc是一家专注于医疗健康领域的数据分析与技术服务商，提供SaaS模式的真实世界证据解决方案、临床决策支持工具及运营优化服务，客户覆盖生物制药企业、医疗机构及生命科学领域相关机构，助力提升诊疗效率、推动医学研究进展。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
FORA vs PLX — 直观对比
营收规模更大
PLX
是对方的1.1倍
$8.0M
营收增速更快
FORA
高出86.9%
-49.9%
净利率更高
FORA
高出37.5%
-60.3%
两年增速更快
FORA
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.0M | $9.1M |
| 净利润 | $-1.8M | $-5.5M |
| 毛利率 | 49.2% | 49.4% |
| 营业利润率 | -24.4% | -51.1% |
| 净利率 | -22.9% | -60.3% |
| 营收同比 | 37.0% | -49.9% |
| 净利润同比 | -1012.2% | -184.8% |
| 每股收益（稀释后） | $-0.06 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FORAPLX
| Q4 25 | $8.0M | $9.1M | ||
| Q3 25 | $7.8M | $17.9M | ||
| Q2 25 | $7.5M | $15.7M | ||
| Q1 25 | $7.1M | $10.1M | ||
| Q4 24 | $5.8M | $18.2M | ||
| Q3 24 | $4.7M | $18.0M | ||
| Q2 24 | $4.8M | $13.5M | ||
| Q1 24 | $4.9M | — |
净利润FORAPLX
| Q4 25 | $-1.8M | $-5.5M | ||
| Q3 25 | $-151.2K | $2.4M | ||
| Q2 25 | $224.8K | $164.0K | ||
| Q1 25 | $-1.1M | $-3.6M | ||
| Q4 24 | $199.7K | $6.5M | ||
| Q3 24 | $-204.9K | $3.2M | ||
| Q2 24 | $-2.6M | $-2.2M | ||
| Q1 24 | $-1.2M | — |
毛利率FORAPLX
| Q4 25 | 49.2% | 49.4% | ||
| Q3 25 | 51.6% | 53.4% | ||
| Q2 25 | 56.8% | 62.5% | ||
| Q1 25 | 55.6% | 19.1% | ||
| Q4 24 | 58.3% | 78.7% | ||
| Q3 24 | 70.1% | 53.4% | ||
| Q2 24 | 62.2% | 29.8% | ||
| Q1 24 | 65.1% | — |
营业利润率FORAPLX
| Q4 25 | -24.4% | -51.1% | ||
| Q3 25 | -6.1% | 11.9% | ||
| Q2 25 | 0.6% | 7.5% | ||
| Q1 25 | -19.8% | -41.0% | ||
| Q4 24 | -24.9% | 39.6% | ||
| Q3 24 | -17.0% | 22.2% | ||
| Q2 24 | -62.2% | -18.0% | ||
| Q1 24 | -36.3% | — |
净利率FORAPLX
| Q4 25 | -22.9% | -60.3% | ||
| Q3 25 | -1.9% | 13.2% | ||
| Q2 25 | 3.0% | 1.0% | ||
| Q1 25 | -16.0% | -35.8% | ||
| Q4 24 | 3.4% | 35.6% | ||
| Q3 24 | -4.4% | 18.0% | ||
| Q2 24 | -53.4% | -16.4% | ||
| Q1 24 | -24.9% | — |
每股收益（稀释后）FORAPLX
| Q4 25 | $-0.06 | $-0.06 | ||
| Q3 25 | $0.00 | $0.03 | ||
| Q2 25 | $0.01 | $0.00 | ||
| Q1 25 | $-0.04 | $-0.05 | ||
| Q4 24 | $0.01 | $0.10 | ||
| Q3 24 | $-0.01 | $0.03 | ||
| Q2 24 | $-0.08 | $-0.03 | ||
| Q1 24 | $-0.04 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.6M | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $29.8M | $48.2M |
| 总资产 | $44.1M | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FORAPLX
| Q4 25 | $31.6M | $14.7M | ||
| Q3 25 | $28.2M | $13.6M | ||
| Q2 25 | $35.6M | $17.9M | ||
| Q1 25 | $35.7M | $19.5M | ||
| Q4 24 | $35.1M | $19.8M | ||
| Q3 24 | $49.4M | $27.4M | ||
| Q2 24 | $48.0M | $23.4M | ||
| Q1 24 | $47.4M | — |
股东权益FORAPLX
| Q4 25 | $29.8M | $48.2M | ||
| Q3 25 | $31.1M | $52.9M | ||
| Q2 25 | $30.9M | $49.9M | ||
| Q1 25 | $30.0M | $45.2M | ||
| Q4 24 | $30.1M | $43.2M | ||
| Q3 24 | $28.4M | $32.4M | ||
| Q2 24 | $27.2M | $28.6M | ||
| Q1 24 | $28.1M | — |
总资产FORAPLX
| Q4 25 | $44.1M | $82.3M | ||
| Q3 25 | $41.3M | $82.3M | ||
| Q2 25 | $48.5M | $78.5M | ||
| Q1 25 | $48.6M | $73.9M | ||
| Q4 24 | $47.2M | $73.4M | ||
| Q3 24 | $57.5M | $61.6M | ||
| Q2 24 | $58.4M | $91.5M | ||
| Q1 24 | $57.5M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.2M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | — | $1.6M |
| 自由现金流率自由现金流/营收 | — | 17.8% |
| 资本支出强度资本支出/营收 | — | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流FORAPLX
| Q4 25 | $3.2M | $2.0M | ||
| Q3 25 | $-439.7K | $-3.7M | ||
| Q2 25 | $-344.5K | $-5.2M | ||
| Q1 25 | $448.2K | $-5.1M | ||
| Q4 24 | $1.7M | $4.0M | ||
| Q3 24 | $764.1K | $4.1M | ||
| Q2 24 | $-23.1K | $-3.6M | ||
| Q1 24 | $-2.2M | — |
自由现金流FORAPLX
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
自由现金流率FORAPLX
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
资本支出强度FORAPLX
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | 0.0% | 2.3% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | 0.0% | 1.3% | ||
| Q1 24 | 0.0% | — |
现金转化率FORAPLX
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | -1.53× | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | 8.76× | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FORA
| Financial Services Revenues | $7.3M | 92% |
| Other | $669.0K | 8% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
